Results 141 to 150 of about 7,154 (184)
EClinicalMedicine, 2023 Background: Nirmatrelvir/ritonavir treatment decreases the hospitalisation rate in immunocompetent patients with COVID-19, but data on efficacy in patients with haematological malignancy are scarce. Here, we describe the outcome of nirmatrelvir/ritonavir
Olimpia Finizio +2 more
exaly +1 more source
Organic Process Research and Development, 2023 Nirmatrelvir (1), a novel and specific inhibitor of the SARS-CoV-2 3C-like protease, was developed by Pfizer scientists in mid 2020. Efforts to develop a scalable process to manufacture nirmatrelvir were undertaken with a great sense of urgency, as ...
Christophe Allais +2 more
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Nirmatrelvir-Ritonavir (Paxlovid)
Canadian Journal of Health TechnologiesCADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the ...
openaire +1 more source
Paxlovid (Nirmatrelvir/Ritonavir): A new approach to Covid-19 therapy?
Biomedicine and Pharmacotherapy, 2023Seyed Mohammadreza Hashemian +2 more
exaly